Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  5.00 0.59% 855.00 840.00 870.00 863.00 849.00 855.00 4,027 08:00:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 636

Maxcyte Share Discussion Threads

Showing 376 to 399 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
13/1/2021
09:54
Level 2 is 4 v 1, so not surprised it's difficult to buy anything... That UT last night at 6.50 was ridiculous, a very clear message that somebody wanted the run of up days to end!
74tom
13/1/2021
09:44
Trying to add another 2750 , nothing doing yet.
assagai
13/1/2021
09:37
Not much time to buy ahead of next news... "...Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021. MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group's CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January."
someuwin
12/1/2021
18:03
Interesting closing share price One UT trade for 100 shares at 650p setting the close. No other trades close to that during the day. When the share price was 610 - 630p all the trades at 617 were actually Buys. Something going on in the background.
acuere
12/1/2021
09:22
Currently you're getting two companies for the price of one. * MXCT which is the 'picks & shovels' gene & cell therapy tools business (with royalties from partner products) * CARMA Cell Therapies - mRNA based cell therapies for cancer and other diseases. With a Phase I clinical trial for ovarian cancer underway. We'll hear more about their plans for CARMA (spin out?, trade sale?, farm in?, IPO?) and clinical progress later this month. Realising value from CARMA should provide a big uplift here.
someuwin
11/1/2021
11:30
It's so quiet, I can still hear that echo :-)
walter walcarpets
11/1/2021
11:24
Echo that.
assagai
11/1/2021
11:12
As an indication of the lack of awareness of Mxct look at the Lse BB. Only 6 posts since July when share price was 217p. And none at all since 24th Nov. Quiet BBs always a good sign for me.
acuere
11/1/2021
09:36
This slide from last November shows the accelerating increase in the number of commercial partners. Second week into 2021 and they bag another one! MXCT will just keep getting bigger and bigger.
someuwin
11/1/2021
08:45
Hi someuwin...it's been on some of our radars for sometime now, but agree that this is still undervalued in the market given its potential. It's hard to find all the undervalued shares in the market....good luck anyway !
multibagger
11/1/2021
08:44
Yes, I'm amazed at the lack of awareness of this stock. It must surely be on it's way to being a multi-billion stock.
someuwin
11/1/2021
08:34
I'm averaging up on MXCT...circa £57,900 order gone in :) Edit: Filled 9259 shares@ 625p Good luck all !
multibagger
11/1/2021
07:54
Excellent news to start the week, and rather surprising how quiet this thread is. MXCT still under the radar?
saucepan
11/1/2021
07:10
11 January 2021 Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs Myeloid to utilize MaxCyte's Flow Electroporation (R) technology and ExPERT(TM) platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma Cambridge, mA and GAITHERSBURG, MD, 11 January 2021 -Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announce the signing of a clinical and commercial licensing agreement. Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform. This agreement enables Myeloid to advance its pipeline programs, including for engineered cell therapies targeting solid tumors, T cell lymphoma, and glioblastoma . In return, MaxCyte is entitled to receive undisclosed development and approval milestones, and sales-based payments, along with other licensing fees. Myeloid's ATAK(TM) platform leverages the unique power of myeloid cells to help patients fighting cancers that, until now, have been very difficult to treat. By targeting myeloid cells, the technology allows for diverse applications and Myeloid's pipeline expansion is ongoing. "We are very excited to be working with MaxCyte, an established leader in cell engineering. This agreement provides long-term access to MaxCyte's unique electroporation technology platform, representing an important enabling step in the continued clinical advancement of targeted cell-based therapies, for patients with few if no options," said Daniel Getts, PhD, CEO of Myeloid. "The ease of use and integration of MaxCyte instruments into our workflow allows us to envision rapid-same-day turnaround of cell treatments for patients presenting with aggressive tumors." Doug Doerfler, President & CEO of MaxCyte, said: "We are proud to support Myeloid's work and are excited about the company's novel approach to engineering and harnessing the innate capabilities of the myeloid cell. This agreement represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in novel cell types. Myeloid's ATAK(TM) technology is being developed for several critical applications in cancer." MaxCyte's ExPERT instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics. About Myeloid Therapeutics Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAK(TM) platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. Myeloid expects to enter the clinic with its two lead programs in the first half of 2021. For more information, visit https://www.myeloidtx.com/ .
someuwin
08/1/2021
16:53
trendy sector at the moment, BEAM going nuts stateside too
davemac3
08/1/2021
15:42
...Yes, peeps buying ahead of news week after next: "Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021. MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group's CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January."
someuwin
08/1/2021
15:17
Looking good here, someuwin. Nice strength to close the week.
saucepan
08/1/2021
08:38
Big demand again. No buy quote available.
someuwin
07/1/2021
17:23
Obviously people have their personal reasons for selling, but for me it would seem daft to sell before the Nasdaq listing. Nasdaq investors are more comfortable with higher valuations and once on Nasdaq we should see a valuation in line with other peers listed there.
acuere
07/1/2021
15:17
Indeed - not surprising not many sellers of the most strategically important company in the genetics space with options in the shape of royalties on most future drugs in the sector. There will be a pullback at some point, from what price?
nimbo1
07/1/2021
14:28
20k @£5.60 at the 1.50 auction bid , so there are hungry buyers. Didn't get done so no real appetite for sellers at these levels. Incidentally CRISPR just hit all time high
assagai
07/1/2021
14:17
Looks like it wants to move up.
someuwin
06/1/2021
10:59
You may be onto something though ..druff2. It looks like MaxCyte is quoting OTC in the US under the ticker MAXC. I'm not sure if the line is liquid, or indeed how long it has existed. The obvious question is whether this is a step in the process of establishing the full Nasdaq quote. To confirm you should be fine trading in either of the UK lines MXCT or MXCL, although the latter is much less liquid and only offered by a small group of brokers. Assuming the Nasdaq listing proceeds, it seems likely, but not certain, that the 2 UK lines will be merged into one at some point. At least one UK line should remain post a full US listing.
rgmgo
06/1/2021
10:18
There is no Nasdaq version. There are 2 lines of stock due to fund raise however you need to buy mxct ticker- some brokers have it as an American share you need to fill out a w8-benn form to buy. No idea why as it’s listed in uk despite being registered in US.
nimbo1
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210421 08:31:47